Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors

Acute Myeloid Leukemia

(2017) Margaret R. O'Donnell et al.   Journal of the National Comprehensive Cancer Network

Minimal residual disease monitoring int(8;21) acute myeloid leukemia based onRUNX1-RUNX1T1fusion quantification on genomic DNA

(2014) Nicolas Duployez et al.   AMERICAN JOURNAL OF HEMATOLOGY

MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia

(2014) Chong Chen et al.   CANCER CELL

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome

(2014) M-T Krauth et al.   LEUKEMIA

Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis

(2014) Andrew M. Brunner et al.   LEUKEMIA RESEARCH

Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta

(2013) Roberto Cairoli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

(2013) S. Opatz et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

(2013) H.-H. Zhu et al.   BLOOD

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

(2013) Montserrat Hoyos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia

(2013) H-A Hou et al.   LEUKEMIA

Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations

(2013) E Manara et al.   LEUKEMIA

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

(2013) C Allen et al.   LEUKEMIA

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

(2012) S. Schwind et al.   BLOOD

Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia

(2012) S. Matsuura et al.   BLOOD

High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations

(2012) M. W. M. Kuhn et al.   BLOOD

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

(2012) P. Paschka et al.   BLOOD

How I treat pediatric acute myeloid leukemia

(2012) J. E. Rubnitz   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

(2012) Véronique Gelsi-Boyer et al.   Journal of Hematology & Oncology

Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation

(2012) Vassiliki E. Mpakou et al.   LEUKEMIA RESEARCH

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches

(2012) Megan A. Hatlen et al.   Frontiers of Medicine

Core-Binding Factor Acute Myeloid Leukemia

(2011) Nikhil A. Sangle et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis

(2011) Mayur Parihar et al.   LEUKEMIA & LYMPHOMA

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

(2010) S. Kayser et al.   BLOOD

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

KITmutations confer a distinct gene expression signature in core binding factor leukaemia

(2010) Sonja C. Lück et al.   BRITISH JOURNAL OF HAEMATOLOGY

Poor survival in t(8;21)(q22;q22)-associated acute myeloid leukaemia with leukocytosis

(2010) Rolf Billström et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98

(2010) Christine von Neuhoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia

(2010) Andrea Corbacioglu et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

(2010) R Guièze et al.   LEUKEMIA

Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome

(2009) Steven A. Gustafson et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

(2009) H. B. Ommen et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

(2009) Gautam Borthakur et al.   CANCER

A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

(2009) E. Iwanaga et al.   HAEMATOLOGICA

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

(2009) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact ofC-KIT,FLT3, andJAK2mutations on clinical outcome

(2009) Jana Marková et al.   LEUKEMIA & LYMPHOMA

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease

(2008) A. J. Mead et al.   BLOOD

Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival

(2008) F. Dayyani et al.   BLOOD

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

(2008) Krzysztof Mrózek et al.   CURRENT OPINION IN ONCOLOGY

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

(2008) S. Abbas et al.   HAEMATOLOGICA

Cooperating gene mutations in acute myeloid leukemia: a review of the literature

(2008) A Renneville et al.   LEUKEMIA

A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

(2008) Steven Lane et al.   LEUKEMIA & LYMPHOMA

Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations

(2008) Pei Lin et al.   MODERN PATHOLOGY

Core Binding Factor Acute Myeloid Leukemia

(2008) Peter Paschka   SEMINARS IN ONCOLOGY

Significance of age in acute myeloid leukemia patients younger than 30 years

(2007) Ursula Creutzig et al.   CANCER